ANTI epilepsy drug Vimpat
(lacosamide) is now available under
the PBS for Australians with
epilepsy who have not responded to
other medications.
It’s an authority-required benefit
which is estimated to cost the PBS
about $16 million over the next five
years, with the announcement
coinciding with the start of National
Epilepsy Awareness Week.The above article was sent to subscribers in Pharmacy Daily's issue from 10 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 May 10
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.